Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139269 | 0.84 | — | — | |
| SCHEMBL1506100 | 0.82 | ALDH1A1 (0.41) | KDM4EMAPTNAMPTKMT2AGAA | |
| SCHEMBL1505765 | 0.81 | MTOR (0.50) | MAPTMTORKMT2AGAASMN1; SMN2 | |
| SCHEMBL2137127 | 0.80 | MAPT (0.45) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1505706 | 0.80 | KDM4E (0.43) | KDM4EMAPTNAMPTKMT2AGAA | |
| SCHEMBL1505581 | 0.80 | KDM4E (0.43) | KDM4EMAPTNAMPTKMT2AGAA | |
| SCHEMBL1505602 | 0.80 | KDM4E (0.42) | KDM4EMAPTMTORNAMPTKMT2A | |
| SCHEMBL2134704 | 0.79 | CDK5 (0.41) | NAMPTKMT2AGAA | |
| SCHEMBL2132461 | 0.79 | ABL1 (0.40) | KDM4EMAPTKMT2ANPC1RAB9A | |
| SCHEMBL2133723 | 0.78 | MAPK1 (0.38) | KDM4EMAPTMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | KDM4E 2925/4885MAPT 2015/4885MTOR 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.